Stock Events

Stock Events

Oncotherpapy Science 

€0.066000
0
-€0.00-5.71%Friday 20:31

Statistics

Day High
0.075
Day Low
0.066
52W High
0.113
52W Low
0.066
Volume
-
Avg. Volume
-
Mkt Cap
22.35M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 9Expected
Q2 2026
Next
-0
0.33
0.66
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-113.06%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.53MRevenue
-5.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 30O.STU. It's not an investment recommendation.
Mitsubishi UFJ Financial Group
3
8306.TSE
NTT
3
9432.TSE
ENEOS
2
5020.TSE
SoftBank
2
9434.TSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Eisai
4523.TSE
Mkt Cap1.69T
Eisai Co., Ltd. focuses on the discovery, development, and commercialization of oncology drugs, directly competing in the cancer treatment market.
Shionogi &.
4507.TSE
Mkt Cap2.12T
Shionogi & Co., Ltd. engages in the development of pharmaceutical products, including therapies for cancer, positioning it as a competitor in the oncology sector.
Chugai Pharmaceutical
4519.TSE
Mkt Cap6.03T
Chugai Pharmaceutical Co., Ltd. specializes in biopharmaceuticals, including cancer treatments, making it a direct competitor in the oncology field.
Daiichi Sankyo.
4568.TSE
Mkt Cap8.21T
Daiichi Sankyo Company, Limited focuses on the development of novel oncology therapies, competing in the same therapeutic area as Oncotherapy Science.
Kyowa Kirin.
4151.TSE
Mkt Cap1.75T
Kyowa Kirin Co., Ltd. works on innovative drug discovery in oncology among other areas, competing for market share in cancer treatment.
Astellas Pharma
4503.TSE
Mkt Cap3.68T
Astellas Pharma Inc. is involved in the development of new therapeutic drugs in oncology, making it a competitor in the cancer treatment market.
Sumitomo Pharma.
4506.TSE
Mkt Cap419.94B
Sumitomo Pharma Co., Ltd. has a focus on creating innovative therapies, including for cancer, positioning it as a competitor in the oncology space.
OtsukaLtd.
4578.TSE
Mkt Cap2.43T
Otsuka Holdings Co., Ltd. has a diversified portfolio that includes developing oncology treatments, making it a competitor in the cancer therapy market.
Fujifilm
4901.TSE
Mkt Cap2.83T
Fujifilm Holdings Corporation, through its bio-CDMO division, is expanding into healthcare, including cancer treatment, positioning it as a competitor.
Nano
4571.TSE
Mkt Cap14.49B
Nippon Shinyaku Co., Ltd. focuses on the research and development of pharmaceuticals, including cancer treatments, making it a competitor in the oncology market.

About

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Show More
CEO
Junichi Shimada
Employees
46
Country
Japan
ISIN
JP3202150003
WKN
000726692

Listings

MU
DE
30O.MU
TSE
JP
4564.TSE
F
DE
30O.F
STU
DE
30O.STU

0 Comments

Share your thoughts

FAQs

What is Oncotherpapy Science stock price today?▼
The current price of 30O.STU is €0.07 EUR — it has decreased by -5.71% in the past 24 hours. Watch Oncotherpapy Science stock price performance more closely on the chart.
What is Oncotherpapy Science stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Oncotherpapy Science stocks are traded under the ticker 30O.STU.
What is Oncotherpapy Science market cap?▼
Today Oncotherpapy Science has the market capitalization of 22.35M
When is the next Oncotherpapy Science earnings date?▼
Oncotherpapy Science is going to release the next earnings report on November 9, 2026.
What were Oncotherpapy Science earnings last quarter?▼
30O.STU earnings for the last quarter are -0 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Oncotherpapy Science revenue for the last year?▼
Oncotherpapy Science revenue for the last year amounts to 4.53M EUR.
What is Oncotherpapy Science net income for the last year?▼
30O.STU net income for the last year is -5.12M EUR.
How many employees does Oncotherpapy Science have?▼
As of November 8, 2026, the company has 46 employees.
In which sector is Oncotherpapy Science located?▼
Oncotherpapy Science operates in the Health & Wellness sector.
When did Oncotherpapy Science complete a stock split?▼
The last stock split for Oncotherpapy Science was on September 26, 2013 with a ratio of 500:1.
Where is Oncotherpapy Science headquartered?▼
Oncotherpapy Science is headquartered in Kawasaki, Japan.